Judo Bio, a stealth-mode biotech firm, pioneers precision therapeutics for genetic diseases, aiming to change lives with innovative receptor targeting.
Judo Bio is a biotech firm focused on developing precision therapeutics targeting specific cell populations to address significant unmet medical needs in genetic diseases and beyond. Leveraging an innovative receptor targeting approach, Judo Bio aims to build a pipeline benefiting patients with both common and rare diseases. Seeded by Atlas Venture and The Column Group, the company operates in stealth mode to pioneer these advancements.
Judo Bio has made notable strides in the biotech industry by attracting high-caliber talent and securing investment from prominent venture capital firms. The company's innovative approach has the potential to revolutionize treatment for genetic diseases, offering new hope to patients worldwide.
